{'52WeekChange': 0.9786885,
 'SandP52WeekChange': 0.0644362,
 'address1': 'The Empire State Building',
 'address2': 'Suite 7530 350 Fifth Avenue',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 24.17,
 'askSize': 800,
 'averageDailyVolume10Day': 398375,
 'averageVolume': 452763,
 'averageVolume10days': 398375,
 'beta': 1.65379,
 'beta3Year': None,
 'bid': 22.19,
 'bidSize': 1000,
 'bookValue': 5.189,
 'category': None,
 'circulatingSupply': None,
 'city': 'New York',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 24.77,
 'dayLow': 23.33,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -13.881,
 'enterpriseToRevenue': None,
 'enterpriseValue': 1122716032,
 'exDividendDate': None,
 'exchange': 'NGM',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fax': '646 224 9585',
 'fiftyDayAverage': 21.749714,
 'fiftyTwoWeekHigh': 27.59,
 'fiftyTwoWeekLow': 9.01,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 32377432,
 'forwardEps': -1.94,
 'forwardPE': -12.443298,
 'fromCurrency': None,
 'fullTimeEmployees': 72,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'heldPercentInsiders': 0.050430004,
 'heldPercentInstitutions': 0.95489,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': 1515110400,
 'lastSplitFactor': '1:4',
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/rocketpharma.com',
 'longBusinessSummary': 'Rocket Pharmaceuticals, Inc., together with its '
                        'subsidiaries, operates as a multi-platform '
                        'biotechnology company that focuses on developing gene '
                        'therapies for rare and devastating pediatric '
                        'diseases. It has clinical-stage lentiviral vector '
                        '(LVV) programs under clinical testing to treat '
                        'fanconi anemia, a genetic defect in the bone marrow '
                        'that reduces production of blood cells or promotes '
                        'the production of faulty blood cells; leukocyte '
                        'adhesion deficiency-I, a genetic disorder that causes '
                        'the immune system to malfunction, and pyruvate kinase '
                        'deficiency, a rare red blood cell autosomal recessive '
                        'disorder that results in chronic non-spherocytic '
                        'hemolytic anemia. It also has additional infantile '
                        'malignant osteopetrosis, a genetic disorder '
                        'characterized by increased bone density and bone mass '
                        'secondary to impaired bone resorption. In addition, '
                        'the company has an adeno-associated virus program for '
                        'Danon disease, a multi-organ lysosomal-associated '
                        'disorder leading to early death due to heart failure. '
                        'It has license agreements with Fred Hutchinson Cancer '
                        'Research Center; Centro de Investigaciones '
                        'Energéticas, Medioambientales y Tecnológicas '
                        '(CIEMAT), Centro de Investigacion Biomedica En Red, '
                        'and Fundacion Instituto de investigacion Sanitaria '
                        'Fundacion Jimenez Diaz; CIEMAT and UCL Business PLC; '
                        'The Regents of the University of California; and '
                        'REGENXBIO Inc. The company also has a research and '
                        'collaboration agreement with Lund University; and '
                        'strategic collaboration agreement with Stanford '
                        'University School of Medicine. Rocket '
                        'Pharmaceuticals, Inc. is headquartered in New York, '
                        'New York.',
 'longName': 'Rocket Pharmaceuticals, Inc.',
 'market': 'us_market',
 'marketCap': 1331489920,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_427906624',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -82483000,
 'nextFiscalYearEnd': 1640908800,
 'open': 24.3,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': -1.16,
 'phone': '646 440 9100',
 'previousClose': 24.78,
 'priceHint': 2,
 'priceToBook': 4.6521487,
 'priceToSalesTrailing12Months': None,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 24.77,
 'regularMarketDayLow': 23.33,
 'regularMarketOpen': 24.3,
 'regularMarketPreviousClose': 24.78,
 'regularMarketPrice': 24.3,
 'regularMarketVolume': 224485,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 55157000,
 'sharesPercentSharesOut': 0.16,
 'sharesShort': 8825589,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 8382070,
 'shortName': 'Rocket Pharmaceuticals, Inc.',
 'shortPercentOfFloat': 0.2515,
 'shortRatio': 16.9,
 'startDate': None,
 'state': 'NY',
 'strikePrice': None,
 'symbol': 'RCKT',
 'threeYearAverageReturn': None,
 'toCurrency': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -1.603,
 'twoHundredDayAverage': 19.384209,
 'volume': 224485,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.rocketpharma.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '10118'}